Specialty drugs continue to comprise a growing portion of costs in workers’ comp – anywhere from 5-8% of total pharmacy spend, according to recent industry data. In fact, individual therapies in the specialty category can cost up to 40 times more than traditional medications. And among the costliest medications in that category are infusibles.
Grand View Research valued the global home infusion therapy market at $35.96 billion in 2023 and expects it to grow at a compound annual growth rate of 8.1% from 2024 to 2030. In 2023, Risk & Insurance featured specialty/infusibles as one of seven drug trends to watch in an article featuring Silvia Sacalis, Healthesystems’ VP of Clinical.
Let’s look at how infusibles fit into the workers’ compensation space and their considerations related to site of care, cost, and claims management.
What Are Infusibles?
Infusibles are drugs that usually involve the administration of medication directly into the patient’s veins through a needle or catheter. Many of these medications are “biologics” – drugs derived from living organisms – which have complex storage/handling and administration requirements.
Continue reading the article in full online at the Healthesystems blog.
